BET bromodomain inhibition as a therapeutic strategy to target c-Myc
about
The basal transcription machinery as a target for cancer therapyBrd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelAThe ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stabilitySmall molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastomaJARID1B is a luminal lineage-driving oncogene in breast cancerBromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cellsDrugging MYCN through an allosteric transition in Aurora kinase APhospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targetingHistone recognition and large-scale structural analysis of the human bromodomain familyBrd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause releaseDisrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancerSmall-molecule inhibition of BRDT for male contraception.Process of Fragment-Based Lead Discovery-A Perspective from NMREpimutational profile of hematologic malignancies as attractive target for new epigenetic therapiesBromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System TumorsThe Impact of External Factors on the Epigenome: In Utero and over LifetimeStrategically targeting MYC in cancerDNA Methylation and Chromatin Remodeling: The Blueprint of Cancer EpigeneticsDrugging the undruggables: exploring the ubiquitin system for drug developmentThe progress of angiogenic factors in the development of leukemiasTargeted drugs in small-cell lung cancerCurrent challenges and novel treatment strategies in double hit lymphomasRegulation of MYC gene expression by aberrant Wnt/β-catenin signaling in colorectal cancerMYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical managementDichotomy in the Epigenetic Mark Lysine Acetylation is Critical for the Proliferation of Prostate Cancer CellsSGF29 and Sry pathway in hepatocarcinogenesisOrigins, genetic landscape, and emerging therapies of small cell lung cancerLinking epithelial-to-mesenchymal-transition and epigenetic modificationsTargeting melanoma by small molecules: challenges aheadMinireview: Conversing with chromatin: the language of nuclear receptorsCombating the epigenome: epigenetic drugs against non-Hodgkin's lymphomaMutual relationships between transcription and pre-mRNA processing in the synthesis of mRNACoordination of nutrient availability and utilization by MAX- and MLX-centered transcription networksEpigenetics: the fine-tuner in inflammatory bowel disease?KATs in cancer: functions and therapiesV. Molecular classification and risk stratification of myelomaMechanisms of epigenetic regulation of leukemia onset and progressionRecent progress toward epigenetic therapies: the example of mixed lineage leukemiaEpigenetic regulators as promising therapeutic targets in acute myeloid leukemiaChromatin targeting drugs in cancer and immunity
P2860
Q21246017-0E529D21-EBBD-4096-A82F-365DD3BF4E18Q24293271-061226EF-19C4-47CB-B02A-DC58A2C6F84CQ24296476-B9BFCC9B-ACB0-41AF-B04C-709CCCB63765Q24296639-BEBC3317-534C-4490-A82A-7DACB1BC7C84Q24299326-BD0745DE-27F6-47AF-A2F2-5D6166C5C338Q24301441-5914A85D-F915-4294-B4A4-39767200E9A2Q24303381-15BE57FE-D094-4FAD-B83C-2CFC9D281B90Q24308867-7514ED8A-D7D1-4D9A-90B8-1523F7741745Q24310431-EDEF1ED4-E38B-4FAD-AA36-8137103663A3Q24315005-FC62E526-922D-482E-A1B7-CA068A5B2D62Q24337204-C489EA17-ADEC-4BB1-AF94-8BEBCF9B8113Q24616901-531C9A42-EBBD-4261-92E2-369CB391D533Q26738768-FB140CA9-04F0-4004-8232-18F2AEA92E9EQ26744080-EFF1E26C-8FE7-4437-A6D9-F68167BEBD89Q26744268-4D783A31-B960-4F72-9B74-FD431A569E28Q26746703-45B82567-0183-4E5E-AB60-7BFAC30C44A3Q26747745-4BD3D32E-92CE-49E1-9FB7-8BC648F4BACDQ26749421-86C9546B-B065-4957-A3A4-8F1AE911A0A2Q26752823-FBB5780A-F398-48C6-A5C6-961EEC82D3C6Q26753835-635FDEE4-EE2C-41BA-9864-96CD6F1082E2Q26767017-E2EFBF58-AE27-439E-904C-B31F9A7B82D7Q26770385-206E71A7-FBFF-40FF-9CF1-6BB76AB7DE1FQ26775423-D267660D-3C12-4503-8A32-6E4EFD4364CEQ26785379-04348402-D953-46CE-8137-7A1F69AAB160Q26795738-1DB15664-1C48-4ABA-844F-A700B3312739Q26795760-755E91F4-0B96-443A-9E2E-3AE2088CA2DCQ26798218-CE1A8347-A50D-4AB0-BDB7-C892B3991567Q26824575-90EAB87A-90D0-4012-AABC-57F2A714F946Q26824642-742F9C2F-10DB-4948-858C-EB65C5B9EDF3Q26829103-84466845-BC2B-407D-8D32-CAB91A831EE6Q26851166-EFF94FCF-68C9-4A40-AFC7-D98B44A3FC71Q26851218-07126E09-0399-45D7-BA36-93575DCFCCAEQ26853482-1586F31D-5BC4-4541-88BF-9241C0C37B1FQ26853555-3EA4C58E-620B-4C6C-B2DB-D128B330E78BQ26859355-FF3B5BE0-8BE1-4A60-89A2-32E1976E8D5DQ26861396-36D7C5D3-C906-4E68-BD58-D0C2EA76C712Q26861785-DF352F55-C02A-42F8-8CC0-56C915D8D9DCQ26863577-927D7168-0767-4A61-B66D-10F265D978EFQ26865149-DFFBAF4C-CA62-48E4-AF16-ABC90E07CC4DQ26999888-E9D066D2-B13C-4FAD-A6E5-A83E6453275C
P2860
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
@ast
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
@en
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
@nl
type
label
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
@ast
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
@en
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
@nl
prefLabel
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
@ast
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
@en
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
@nl
P2093
P2860
P50
P3181
P1433
P1476
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
@en
P2093
Anna C Schinzel
Constantine S Mitsiades
Ghayas C Issa
Hannah M Jacobs
Irene M Ghobrial
Jake E Delmore
James E Bradner
Junwei Shi
Marta Chesi
P2860
P304
P3181
P356
10.1016/J.CELL.2011.08.017
P407
P50
P577
2011-09-16T00:00:00Z